Targeted protein degradation (TPD) using proteolysis targeting chimeras (PROTACs) and
molecular glue degraders has arisen as a powerful therapeutic modality for eliminating …

Anticancer-targeted therapies inhibit various kinases implicated in cancer and have been
used in clinical settings for decades. However, many cancer-related targets are proteins …

Immunomodulatory drugs are a class of drugs approved for the treatment of multiple
myeloma. These compounds exert their clinical effects by inducing interactions between the …

The protein cereblon (CRBN) is a substrate receptor of the cullin 4-really interesting new
gene (RING) E3 ubiquitin ligase complex CRL4 CRBN. Targeting CRBN mediates selective …

Cullin-RING ligases (CRLs) are the largest class of E3 ubiquitin ligases regulating the
stability and subsequent activity of a large number of important proteins responsible for the …

Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug
discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists …

Background Cereblon (CRBN) has emerged as a vital E3 ubiquitin ligase for Proteolysis-
targeting chimera (PROTAC) design. However, few studies focus on the physiological …

Protein ubiquitylation regulates numerous pathways, and the diverse information encoded
by various forms of ubiquitylation is known as the ubiquitin code. Recent studies revealed …

Recently, the development of protein degraders (protein-degrading compounds) has
prominently progressed. There are two remarkable classes of protein degraders: proteolysis …

The drug discovery landscape has undergone a significant transformation over the past
decade, owing to research endeavors in a wide range of areas leading to strategies for …